Immuno-Oncology:

 
 
Alector's therapeutics repolarize all of the innate immune cells in the tumor microenvironment, enabling activation of T-cells that can then attack the tumor.

Alector's therapeutics repolarize all of the innate immune cells in the tumor microenvironment, enabling activation of T-cells that can then attack the tumor.

 
 

In oncology, the mechanism of disease is clear. Cancer is the result of a suppressed immune system. The cancer recruits immune cells that would typically be its antagonists to promote the growth of the tumor and suppress immune responses. Traditional therapies have focused on reactivating suppressed T cells. Unfortunately, this approach has had limited success in curing disease, largely because other highly suppressive cells, including innate immune cells, make these therapies ineffective. By changing the function of innate immune cells and creating a permissive, not hostile environment for T cell function, we can empower the immune system to work on its own behalf to eradicate cancer.

 
Immune therapies have transformed cancer treatment, but these first-generation therapies are not effective for many patients. Alector’s therapeutics address that unmet need.
— Arnon Rosenthal, CEO